Ionis Pharmaceuticals, Inc.
56.02USD
-0.6900 (-1.22%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.92▼ | $-0.81 | 1 | 5 |
| Next quarter | $-0.89▼ | $-0.62 | 0 | 5 |
| Current year | $-2.72▼ | $-2.56 | 4 | 1 |
| Next year | $-1.08▼ | $-0.62 | 4 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.88 | $-0.42 | +0.45 (+51.7%) |
| 2026-03-31 | $-0.78 | $-0.3 | +0.47 (+60.9%) |
| 2025-12-31 | $-1.22 | $-1.15 | +0.07 (+5.6%) |
| 2025-09-30 | $-1.05 | $-0.61 | +0.44 (+41.8%) |
267 ratings from 32 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Morgan Stanley | Maintained | Overweight | $110 $104 | Sep 8, 2026 |
| Goldman Sachs | Maintained | Neutral | $69 $56 | Sep 8, 2026 |
| BMO Capital | Maintained | Market Perform | $61 $54 | Sep 8, 2026 |
| Canaccord Genuity | Maintained | Buy | $95 $85 | Sep 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115 $100 | Sep 8, 2026 |
| Needham | Reiterated | Buy | $86 | Sep 4, 2026 |
| BMO Capital | Maintained | Market Perform | $60 $61 | Sep 4, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $115 | Sep 4, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $115 | Aug 31, 2026 |
| BMO Capital | Initiated from Outperform | Market Perform | $60 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $72 $76 | Aug 3, 2026 |
| Wells Fargo | Maintained | Overweight | $100 $95 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $125 $115 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $106 $89 | Jul 21, 2026 |
| Wolfe Research | Downgraded from Outperform | Peer Perform | — | Jul 16, 2026 |
| RBC Capital | Maintained | Outperform | $100 $85 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $130 $125 | Jul 10, 2026 |
| Morgan Stanley | Maintained | Overweight | $130 $110 | Jul 10, 2026 |
| Barclays | Maintained | Overweight | $115 $90 | Jul 10, 2026 |
| Canaccord Genuity | Maintained | Buy | $110 $95 | Jul 10, 2026 |
| Citigroup | Maintained | Buy | $115 $100 | Jul 10, 2026 |
| Jefferies | Maintained | Buy | $113 $90 | Jul 9, 2026 |
| Needham | Maintained | Buy | $105 $86 | Jul 9, 2026 |
| Goldman Sachs | Maintained | Neutral | $74 $75 | Jun 25, 2026 |
| Leerink Partners | Maintained | Outperform | $122 $129 | Jun 25, 2026 |
154 filings from 24 insiders · 21 buy / 27 sell over 6m
Officers and directors of IONS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BENNETT C FRANKOfficer, EVP, Chief Scientific Officer | Other | 110 | $51.31 | $6k | Aug 31, 2026 |
| O'NEIL PATRICK R.Officer, EVP CLO & General Counsel | Other | 63 | $51.31 | $3k | Aug 31, 2026 |
| Monia Brett PDirector; Officer, Chief Executive Officer | Other | 98 | $51.31 | $5k | Aug 31, 2026 |
| Birchler BrianOfficer, EVP, Corp and Development Ops | Other | 58 | $51.31 | $3k | Aug 31, 2026 |
| HAYDEN MICHAEL REUBENDirector | Buyindirect | 20.0k | $51.60 | $1.06M | Jul 31, 2026 |
| BERTHELSEN SPENCER RDirector | Other | 5.2k | — | — | Jul 15, 2026 |
| HERMAN JOAN EDirector | Other | 5.2k | — | — | Jul 15, 2026 |
| DIAZ ALLENE M.Director | Exercise | 10.1k | $47.11 | $476k | Jul 7, 2026 |
| KORDASIEWICZ HOLLY BOfficer | Sell | 362 | $84.30 | $31k | Jul 7, 2026 |
| DIAZ ALLENE M.Director | Sell | 10.1k | $85.42 | $864k | Jul 7, 2026 |
| BENNETT C FRANKOfficer | Sell | 20.5k | $83.58 | $1.74M | Jul 7, 2026 |
| KLEIN JOSEPH S IIIDirector | Exercise | 11.5k | $39.94 | $460k | Jul 1, 2026 |
| KLEIN JOSEPH S IIIDirector | Sell | 11.5k | $79.04 | $910k | Jul 1, 2026 |
| BAROLDI JOSEPHOfficer | Exerciseindirect | 5.6k | $32.60 | $277k | Jun 26, 2026 |
| SCHNEIDER EUGENEOfficer | Exercise | 26.0k | $60.89 | $1.58M | Jun 26, 2026 |
| MONIA BRETT PChief Executive Officer | Exercise | 85.6k | $32.60 | $4.00M | Jun 26, 2026 |
| BAROLDI JOSEPHOfficer | Sellindirect | 5.6k | $80.16 | $452k | Jun 26, 2026 |
| SCHNEIDER EUGENEOfficer | Sell | 26.0k | $81.05 | $2.11M | Jun 26, 2026 |
| MONIA BRETT PChief Executive Officer | Sell | 85.6k | $78.41 | $6.83M | Jun 26, 2026 |
| O'NEIL PATRICK RGeneral Counsel | Sell | 3.1k | $80.00 | $246k | Jun 26, 2026 |
No analyst notes on IONS yet.
Analyst Ratings
22 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 9 | 10 | 5 | 0 | 0 | Buy1.83 |
| 1 mo ago | 9 | 10 | 5 | 0 | 0 | Buy1.83 |
| 2 mo ago | 9 | 10 | 4 | 0 | 0 | Buy1.78 |
| 3 mo ago | 8 | 12 | 4 | 0 | 0 | Buy1.83 |